Arch Therapeutics, Inc. (ARTH)
USD 0.16
(-10.93%)
USD 0.16
(-10.93%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 5.64 Million USD | 115.97% |
| 2022 | 2.61 Million USD | 492.32% |
| 2021 | -666.63 Thousand USD | -186.1% |
| 2020 | -233 Thousand USD | 89.31% |
| 2019 | -2.18 Million USD | 53.29% |
| 2018 | -4.66 Million USD | 22.13% |
| 2017 | -5.99 Million USD | -47.69% |
| 2016 | -4.05 Million USD | -61.09% |
| 2015 | -2.51 Million USD | -2161.03% |
| 2014 | 122.24 Thousand USD | -68.44% |
| 2013 | 387.38 Thousand USD | -80.68% |
| 2012 | 2 Million USD | 11288.46% |
| 2011 | -17.92 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 7.07 Million USD | 25.28% |
| 2024 Q3 | 9.35 Million USD | 16.52% |
| 2024 Q2 | 8.03 Million USD | 13.5% |
| 2023 Q1 | 3.74 Million USD | 43.13% |
| 2023 Q4 | 5.64 Million USD | 87.96% |
| 2023 FY | 5.64 Million USD | 115.97% |
| 2023 Q3 | 3 Million USD | 53.96% |
| 2023 Q2 | 1.95 Million USD | -47.86% |
| 2022 Q1 | 511.88 Thousand USD | 176.79% |
| 2022 FY | 2.61 Million USD | 492.32% |
| 2022 Q4 | 2.61 Million USD | 69.28% |
| 2022 Q2 | 1.54 Million USD | 201.94% |
| 2022 Q3 | 1.54 Million USD | -0.04% |
| 2021 FY | -666.63 Thousand USD | -186.1% |
| 2021 Q1 | 896.88 Thousand USD | 484.92% |
| 2021 Q2 | -3.78 Million USD | -521.96% |
| 2021 Q3 | -2.17 Million USD | 42.42% |
| 2021 Q4 | -666.63 Thousand USD | 69.41% |
| 2020 Q4 | -233 Thousand USD | 81.89% |
| 2020 FY | -233 Thousand USD | 89.31% |
| 2020 Q1 | -3.02 Million USD | -38.67% |
| 2020 Q2 | -1.78 Million USD | 40.83% |
| 2020 Q3 | -1.28 Million USD | 28.08% |
| 2019 Q3 | -3.18 Million USD | -62.65% |
| 2019 Q2 | -1.95 Million USD | 42.08% |
| 2019 Q1 | -3.37 Million USD | 27.63% |
| 2019 Q4 | -2.18 Million USD | 31.48% |
| 2019 FY | -2.18 Million USD | 53.29% |
| 2018 Q4 | -4.66 Million USD | 28.07% |
| 2018 Q2 | -3.37 Million USD | 31.87% |
| 2018 Q1 | -4.95 Million USD | 17.28% |
| 2018 Q3 | -6.48 Million USD | -92.1% |
| 2018 FY | -4.66 Million USD | 22.13% |
| 2017 Q4 | -5.99 Million USD | 2.83% |
| 2017 FY | -5.99 Million USD | -47.69% |
| 2017 Q3 | -6.16 Million USD | 14.69% |
| 2017 Q2 | -7.23 Million USD | -138.39% |
| 2017 Q1 | -3.03 Million USD | 25.27% |
| 2016 FY | -4.05 Million USD | -61.09% |
| 2016 Q4 | -4.05 Million USD | 14.91% |
| 2016 Q1 | -1.57 Million USD | 37.29% |
| 2016 Q3 | -4.76 Million USD | -699.12% |
| 2016 Q2 | -596.89 Thousand USD | 62.22% |
| 2015 Q3 | -1.81 Million USD | -327.1% |
| 2015 Q1 | 175.85 Thousand USD | 43.85% |
| 2015 FY | -2.51 Million USD | -2161.03% |
| 2015 Q4 | -2.51 Million USD | -39.11% |
| 2015 Q2 | 797.49 Thousand USD | 353.5% |
| 2014 Q4 | 122.24 Thousand USD | 114.39% |
| 2014 FY | 122.24 Thousand USD | -68.44% |
| 2014 Q3 | -849.52 Thousand USD | 49.46% |
| 2014 Q2 | -1.68 Million USD | -81153.42% |
| 2014 Q1 | 2074.00 USD | -99.46% |
| 2013 Q1 | -3142.00 USD | -100.16% |
| 2013 Q3 | -476.36 Thousand USD | -121.08% |
| 2013 Q4 | 387.38 Thousand USD | 181.32% |
| 2013 Q2 | 2.25 Million USD | 72007.03% |
| 2013 FY | 387.38 Thousand USD | -80.68% |
| 2012 FY | 2 Million USD | 11288.46% |
| 2012 Q1 | -10 Thousand USD | 44.21% |
| 2012 Q3 | -19.93 Thousand USD | -294.93% |
| 2012 Q4 | 2 Million USD | 10159.85% |
| 2012 Q2 | -5048.00 USD | 49.52% |
| 2011 FY | -17.92 Thousand USD | 0.0% |
| 2011 Q4 | -17.92 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | 431273.282% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 86.801% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 2362.787% |
| Rebus Holdings, Inc. | 305 Thousand USD | -1751.925% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 189.592% |
| Qrons Inc. | 351.42 Thousand USD | -1507.267% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -807.567% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 86.996% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 27777.234% |
| Skye Bioscience, Inc. | -5.72 Million USD | 198.724% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 64.167% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | -37.162% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -1305.595% |
| SQZ Biotechnologies Company | -36.23 Million USD | 115.587% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | -151.908% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -509.195% |
| Mesoblast Limited | 55.85 Million USD | 89.888% |
| Marizyme, Inc. | 18.56 Million USD | 69.582% |
| Genus plc | 190.6 Million USD | 97.037% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | -152.629% |
| Pharming Group N.V. | 109.8 Million USD | 94.856% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -556.603% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -365.312% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -730.643% |
| ContraFect Corporation | -6.02 Million USD | 193.733% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -4095.196% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -388.855% |
| IMV Inc. | 7.67 Million USD | 26.363% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | -2.662% |
| MultiCell Technologies, Inc. | 90.04 USD | -6273078.587% |
| ONE Bio Corp. | 9.04 Million USD | 37.518% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 869.556% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 56.37% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | -312.901% |
| Q BioMed Inc. | 4.06 Million USD | -39.122% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 81.513% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -460.512% |
| Biomind Labs Inc. | 711.4 Thousand USD | -693.977% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 90.671% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | -182.504% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 55.895% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -1470.257% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -3940.206% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -28330.916% |
| Curative Biotechnology, Inc. | 2.2 Million USD | -156.513% |
| GB Sciences, Inc. | 1.74 Million USD | -223.26% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 3173.307% |
| HST Global, Inc. | 96.79 Thousand USD | -5735.515% |
| CSL Limited | 10.52 Billion USD | 99.946% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -2639.042% |
| Halberd Corporation | 144.72 Thousand USD | -3802.937% |
| Enzolytics Inc. | 981.65 Thousand USD | -475.392% |
| Agentix Corp. | 37.63 Thousand USD | -14909.885% |
| Resverlogix Corp. | 6.45 Million USD | 12.442% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 939.171% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 100.278% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 112.015% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 20.119% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -108.534% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 163.896% |
| AVAX Technologies, Inc. | -5.9 Million USD | 195.683% |
| Zenith Capital Corp. | 10.06 Thousand USD | -56024.503% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.532% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -2718.098% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | -136.726% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -3333.472% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 30935.08% |
| Kadimastem Ltd | -253.1 Thousand USD | 2331.658% |
| Helix BioMedix, Inc. | -2.57 Million USD | 319.778% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 72.143% |
| BioStem Technologies, Inc. | 4.47 Million USD | -26.305% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -2706.588% |
| LadRx Corporation | -2.03 Million USD | 377.361% |
| Cell Source, Inc. | 9.23 Million USD | 38.817% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -789.273% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -789.273% |
| NovAccess Global Inc. | 2.17 Million USD | -159.282% |
| Affymax, Inc. | -5.59 Million USD | 200.918% |
| Itoco Inc. | 228.3 Thousand USD | -2374.046% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -4053.549% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | -13.947% |
| Mobile Lads Corp. | 484.23 Thousand USD | -1066.459% |
| CytoDyn Inc. | 20.26 Million USD | 72.123% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 873109.274% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 61042.628% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 26.702% |
| SYBLEU INC | 473.71 Thousand USD | -1092.359% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | -26.73% |
| International Stem Cell Corporation | 2.59 Million USD | -118.084% |
| Bioxytran, Inc. | 1.89 Million USD | -197.453% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -8949.99% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -158.993% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | -64.484% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 33.96% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -631.079% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 551.87% |
| Neutra Corp. | 52.18 Thousand USD | -10723.328% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 326.933% |
| PureTech Health plc | -167.19 Million USD | 103.378% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 2406.323% |
| IXICO plc | -4.44 Million USD | 227.084% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 57.271% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 89.702% |
| CSL Limited | 10.52 Billion USD | 99.946% |
| Cellectis S.A. | -43.81 Million USD | 112.89% |